AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12368670 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 169
Study 9839762 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 19
Study 9839762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 19
Study 9839762 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil + Cimetidine (5 mg + 800 mg)
Number of subjects: 19
Study 7868435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer conditioning (heart rate of 145 beats/min at 25 min/day for 3 days/wk)
Number of subjects: 38
Study 7868435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer conditioning
Number of subjects: 38
Study 7868435 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising pregnant control women
Number of subjects: 38
Study 2631519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1200 mg/day
Number of subjects: 208
Study 2631519 — intervention group
Group type: COMPARATOR
Intervention: Combination of acetylsalicylic acid (ASA, 1050 mg/day) and dipyridamole (D, 150 mg/day)
Number of subjects: 208
Study 1023953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide 40 ml
Number of subjects: 200
Study 1023953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate 30 ml
Number of subjects: 200
Study 1023953 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium trisilicate 30 ml
Number of subjects: 200
Study 1023953 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg alone
Number of subjects: 200
Study 31521645 — intervention group
Group type: EXPERIMENTAL
Intervention: DK crush stenting
Number of subjects: 482
Study 31521645 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting (PS)
Number of subjects: 482
Study 27940183 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus navigation
Number of subjects: 0
Study 27940183 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 0
Study 25863464 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive task-oriented training on the tilt table
Number of subjects: 39
Study 25863464 — intervention group
Group type: COMPARATOR
Intervention: Tilt table group
Number of subjects: 39
Study 25863464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 22999847 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (subacromial, intra-articular, intra-articular combined with subacromial)
Number of subjects: 191
Study 22999847 — intervention group
Group type: COMPARATOR
Intervention: Medication (control group IV)
Number of subjects: 191
Study 21332807 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndet bar
Number of subjects: 0
Study 21332807 — intervention group
Group type: COMPARATOR
Intervention: One soap bar
Number of subjects: 0
Study 21332807 — intervention group
Group type: COMPARATOR
Intervention: Both soap bars
Number of subjects: 0
Study 19769472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) light exposure
Number of subjects: 19
Study 19769472 — intervention group
Group type: COMPARATOR
Intervention: Non-UV (control) exposure
Number of subjects: 19
Study 17163358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 1.5 mcg/die plus hydrochlorothiazide
Number of subjects: 42
Study 17163358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mineral integrates)
Number of subjects: 42
Study 17163358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol plus hydrochlorothiazide
Number of subjects: 42
Study 15120537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfluent aphasia group
Number of subjects: 0
Study 15120537 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15120537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluent aphasia group
Number of subjects: 0
Study 15120537 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 15120537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfluent aphasic participants
Number of subjects: 0
Study 15120537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluent aphasic participants
Number of subjects: 0
Study 10775552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (255 mmol/d)
Number of subjects: 20
Study 10775552 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (50 mmol/d)
Number of subjects: 20
Study 9322806 — intervention group
Group type: EXPERIMENTAL
Intervention: tolrestat (200 mg daily)
Number of subjects: 18
Study 9322806 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 1587168 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDR)
Number of subjects: 181
Study 1587168 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 181
Study 1587168 — intervention group
Group type: EXPERIMENTAL
Intervention: FDRs with two or more afflicted FDRs
Number of subjects: 181
Study 1587168 — intervention group
Group type: EXPERIMENTAL
Intervention: FDRs with one afflicted FDR
Number of subjects: 181
Study 1587168 — intervention group
Group type: EXPERIMENTAL
Intervention: FDRs
Number of subjects: 181
Study 1587168 — intervention group
Group type: EXPERIMENTAL
Intervention: Male FDRs over the age of 50
Number of subjects: 181
Study 1587168 — intervention group
Group type: COMPARATOR
Intervention: Age-matched male controls
Number of subjects: 181
Study 3919803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for one month
Number of subjects: 16
Study 3919803 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg daily for one month
Number of subjects: 16
Study 30195986 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Caring and Relating with Empathy intervention (16-week, 2-hour sessions)
Number of subjects: 44
Study 30195986 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-controlled group
Number of subjects: 44
Study 30195986 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Caring and Relating with Empathy intervention
Number of subjects: 44
Study 29030237 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS-guided ablation
Number of subjects: 128
Study 29030237 — intervention group
Group type: COMPARATOR
Intervention: CFS-blinded ablation
Number of subjects: 128
Study 27030891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hestia criteria combined with NT-proBNP testing
Number of subjects: 550
Study 27030891 — intervention group
Group type: COMPARATOR
Intervention: Direct discharge (Hestia criteria alone)
Number of subjects: 550
Study 22592579 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in LLINs area
Number of subjects: 0
Study 22592579 — intervention group
Group type: COMPARATOR
Intervention: Control area with untreated nets
Number of subjects: 0
Study 20925642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg twice daily)
Number of subjects: 150
Study 20925642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg twice daily) + Topical honey ointment
Number of subjects: 150
Study 20925642 — intervention group
Group type: COMPARATOR
Intervention: Standard burn treatment (Control group)
Number of subjects: 150
Study 18569935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR)
Number of subjects: 2
Study 18569935 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 2
Study 15377823 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUD)
Number of subjects: 0
Study 15377823 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 0
Study 12419025 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology consultation
Number of subjects: 0
Study 12419025 — intervention group
Group type: COMPARATOR
Intervention: Usual care consultation
Number of subjects: 0
Study 11090092 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg orally per day, increased to 800 mg/d if tolerable)
Number of subjects: 51
Study 11090092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9200358 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf
Number of subjects: 871
Study 8475869 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release gemfibrozil 1,200 mg once daily
Number of subjects: 655
Study 8475869 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 655
Study 3894608 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated bovine rotavirus vaccine strain RIT 4237
Number of subjects: 331
Study 3894608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 31562140 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolled practice nurse-led asthma care
Number of subjects: 180
Study 30318515 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib-gemcitabine
Number of subjects: 156
Study 30318515 — intervention group
Group type: COMPARATOR
Intervention: Placebo-gemcitabine
Number of subjects: 156
Study 26067078 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned chickpea (200 g per day)
Number of subjects: 12
Study 26067078 — intervention group
Group type: EXPERIMENTAL
Intervention: Raffinose (5 g)
Number of subjects: 12
Study 26067078 — intervention group
Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 12
Study 21684626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 96
Study 21684626 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 96
Study 20687863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 15
Study 20687863 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 15
Study 20687863 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 15
Study 18426261 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 63
Study 18426261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 15883316 — intervention group
Group type: EXPERIMENTAL
Intervention: AN1792 (225 microg) plus QS-21 (50 microg)
Number of subjects: 372
Study 15883316 — intervention group
Group type: COMPARATOR
Intervention: CSF examination in antibody responders (n = 11)
Number of subjects: 372
Study 15883316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 372
Study 14562195 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination protocol (0-7-21 days) with combined hepatitis A/B vaccine (Twinrix(R))
Number of subjects: 0
Study 14562195 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination scheme (0-1-6 months) with combined hepatitis A/B vaccine (Twinrix(R))
Number of subjects: 0
Study 10379125 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-managed care (Group A)
Number of subjects: 1050
Study 10379125 — intervention group
Group type: COMPARATOR
Intervention: Obstetrician-managed care (Group B)
Number of subjects: 1050
Study 8818378 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Number of subjects: 46
Study 8818378 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsion Checklist (CC)
Number of subjects: 46
Study 8818378 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Item YBOCS plus the 4-item Disability scale
Number of subjects: 46
Study 29193414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular health promotion intervention
Number of subjects: 229
Study 29193414 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study 28404069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) for 12 weeks
Number of subjects: 267
Study 28404069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) for 24 weeks
Number of subjects: 267
Study 28404069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) plus ribavirin (weight-based 1000 mg or 1200 mg) for 12 weeks
Number of subjects: 267
Study 28404069 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (all groups)
Number of subjects: 267
Study 23653143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention for managing behavioral symptoms
Number of subjects: 119
Study 22633301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (≤4.5 mmol/L)
Number of subjects: 6496
Study 22633301 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperglycemia (>8.3 mmol/L)
Number of subjects: 6496
Study 22633301 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia (4.5-5.5 mmol/L)
Number of subjects: 6496
Study 22633301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic patients (>8.3 mmol/L)
Number of subjects: 6496
Study 20881891 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole
Number of subjects: 72
Study 20881891 — intervention group
Group type: COMPARATOR
Intervention: 20 mg tamoxifen
Number of subjects: 72
Study 17387127 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with optimal medical therapy
Number of subjects: 2287
Study 17387127 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2287
Study 15608427 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL) 2 preconditioning followed by vaccination with virus-modified autologous tumor cells
Number of subjects: 20
Study 15608427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with virus-modified tumor cells
Number of subjects: 20
Study 11880960 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg given by mouth 3 times per day for 2 days)
Number of subjects: 131
Study 11880960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 10734323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion of 50 microg/kg/hour following a bolus dose of 0.1 microg/kg
Number of subjects: 62
Study 10734323 — intervention group
Group type: COMPARATOR
Intervention: Atracurium infusion of 400 microg/kg/hour following a bolus dose of 0.5 microg/kg
Number of subjects: 62
Study 7485324 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 54
Study 7485324 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (Dilantin)
Number of subjects: 54
Study 2104067 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 2104067 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 0
Study 33863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol once daily
Number of subjects: 29
Study 33863 — intervention group
Group type: COMPARATOR
Intervention: Propranolol four times daily
Number of subjects: 29
Study 33863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol once daily (extended treatment)
Number of subjects: 29
Study 31469016 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted correction of benign ureteral stricture
Number of subjects: 36
Study 28640770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 vs. 1 (no sparring partner change)
Number of subjects: 20
Study 28640770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 vs. 2
Number of subjects: 20
Study 28640770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 vs. 4
Number of subjects: 20
Study 28640770 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 2 m ring size
Number of subjects: 20
Study 28640770 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 4 m ring size
Number of subjects: 20
Study 28640770 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 × 6 m ring size
Number of subjects: 20
Study 28640770 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 20
Study 25511354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy (TPbx)
Number of subjects: 75
Study 25511354 — intervention group
Group type: COMPARATOR
Intervention: Transrectal prostate biopsy
Number of subjects: 75
Study 23881187 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-educator network intervention
Number of subjects: 160
Study 23881187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 20236794 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal warm-up (WU) program
Number of subjects: 45
Study 20236794 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 minutes of vocal rest)
Number of subjects: 45
Study 19449366 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 2751
Study 19449366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2751
Study 19449366 — intervention group
Group type: COMPARATOR
Intervention: Active control/usual care
Number of subjects: 2751
Study 16436649 — intervention group
Group type: EXPERIMENTAL
Intervention: IM interferon beta‐1a (IFNbeta‐1a) 30 microg IM once weekly for up to 5 years
Number of subjects: 383
Study 16436649 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (placebo in CHAMPS)
Number of subjects: 383
Study 16436649 — intervention group
Group type: EXPERIMENTAL
Intervention: IM interferon beta‐1a (IFNbeta‐1a)
Number of subjects: 383
Study 15522040 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing
Number of subjects: 60
Study 15522040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting
Number of subjects: 60
Study 15522040 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lying
Number of subjects: 60
Study 11163733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg, n=12)
Number of subjects: 24
Study 11163733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 24
Study 9233974 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially designed, physiologic circumcision restraint chair
Number of subjects: 80
Study 9233974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier dipped in 24% sucrose solution
Number of subjects: 80
Study 9233974 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine hydrochloride
Number of subjects: 80
Study 9233974 — intervention group
Group type: COMPARATOR
Intervention: Control group (rigid plastic restraint board, standard DPNB, pacifier dipped in water)
Number of subjects: 80
Study 9233974 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels
Number of subjects: 80
Study 8104270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1014 patients)
Number of subjects: 2006
Study 8104270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (992 patients)
Number of subjects: 2006
Study 3943286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp-function work test (20 W/min)
Number of subjects: 12
Study 3943286 — intervention group
Group type: COMPARATOR
Intervention: Step-function work test
Number of subjects: 12
Study 3943286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp-function work test
Number of subjects: 12
Study 3943286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp-function work test with steady-state period
Number of subjects: 12
Study 31034856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Number of subjects: 152
Study 31034856 — intervention group
Group type: COMPARATOR
Intervention: 2 iStent Trabecular Micro Bypass devices
Number of subjects: 152
Study 29183844 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) twice daily (BID)
Number of subjects: 263
Study 29183844 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30) BID
Number of subjects: 263
Study 29183844 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 263
Study 29183844 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 263
Study 26850806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromasticks containing essential oils (Bergamot, Sandalwood, Frankincense, Mandarin, Lavender)
Number of subjects: 65
Study 24358145 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently insufficient 25(OH)D (GLL <50 nmol/l)
Number of subjects: 217
Study 24358145 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently sufficient 25(OH)D (GHH >50 nmol/l)
Number of subjects: 217
Study 24358145 — intervention group
Group type: COMPARATOR
Intervention: Low levels of 25(OH)D
Number of subjects: 217
Study 20961233 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy plus topical tetrahydrocurcuminoid cream
Number of subjects: 10
Study 20961233 — intervention group
Group type: COMPARATOR
Intervention: Targeted narrowband UVB monotherapy
Number of subjects: 10
Study 19008798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole as an add-on therapy to L-DOPA and amantadin
Number of subjects: 78
Study 15987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of ST-segment depression in all leads
Number of subjects: 5192
Study 15987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of ST-segment depression
Number of subjects: 5192
Study 15987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal inferior ST-segment elevation
Number of subjects: 5192
Study 15987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior ST-segment elevation
Number of subjects: 5192
Study 15987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of ST-segment depression
Number of subjects: 5192
Study 15987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak levels of creatine kinase during index episode of ACS
Number of subjects: 5192
Study 11863119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IVC) pulse therapy (0.75 - 1.0 g/m2 body surface area) combined with oral corticosteroid (up to 1 mg/kg/day) for 6 months
Number of subjects: 20
Study 11863119 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐filtration plasmapheresis (DFPP) combined with corticosteroid (up to 1 mg/kg/day) performed 1-2 times weekly for 6 months
Number of subjects: 20
Study 11863119 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy individuals)
Number of subjects: 20
Study 10491062 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen cultured human allogenic epidermal sheets
Number of subjects: 10